Concepedia
Statistics
Publications
15
Citations
519
H-Index
14
Active since
1997
Affiliations
Abbott Fund(Current)
Merck & Co., Inc., Rahway, NJ, USA (United States)
Ravi Kurukulasuriya is an author at Abbott Fund specializing in medicinal chemistry, pharmacology, and drug discovery.
Publications per year
1997–2024
2,2,2-Trifluoroethyl Formate: A Versatile and Selective Reagent for the Formylation of Alcohols, Amines, and<i>N</i>-Hydroxylamines
David R. Hill, C.‐N. HSIAO, Ravi Kurukulasuriya et al. · Organic Letters · 2001 · 99 citations
Natural Sciences, Chemistry, Organic Chemistry +3
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2
Heike Schönherr, Pelin Ayaz, Alexander M. Taylor et al. · Proceedings of the National Academy of Sciences · 2024 · 66 citations · Full text
Pharmacy, Medicinal Chemistry, Pharmacology +14
Discovery of Novel Indoline Cholesterol Ester Transfer Protein Inhibitors (CETP) through a Structure-Guided Approach
Jonathan E. Wilson, Ravi Kurukulasuriya, Mikhail Reibarkh et al. · ACS Medicinal Chemistry Letters · 2016 · 53 citations · Full text
Pharmacy, Medicinal Chemistry, Pharmacology +13
Synthesis of Purines and Other Fused Imidazoles from Acyclic Amidines and Guanidines
Bruce G. Szczepankiewicz, Jeffrey J. Rohde, Ravi Kurukulasuriya · Organic Letters · 2005 · 44 citations
Natural Sciences, Chemistry, Medicinal Chemistry +13
Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy
Hongjun Zhang, K. Liu, Qinglin Pu et al. · ACS Medicinal Chemistry Letters · 2019 · 44 citations · Full text
Pharmacy, Medicinal Chemistry, Oncology +16
1–5 of 15